Alkuperäiskieli | Englanti |
---|---|
Sivut | e77-e79 |
Julkaisu | Diabetes Care |
Vuosikerta | 45 |
Numero | 4 |
DOI - pysyväislinkit | |
Tila | Julkaistu - huhtik. 2022 |
OKM-julkaisutyyppi | B1 Artikkeli tiedelehdessä |
Pääsy asiakirjaan
- Type 1 Diabetes in Children With Genetic Risk May Be Predicted Very Early With a Blood miRNALopullinen julkaistu versio, 12,6 MBLisenssi: CC BY
Muut tiedostot ja linkit
Viittausmuodot
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
julkaisussa: Diabetes Care, Vuosikerta 45, Nro 4, 04.2022, s. e77-e79.
Tutkimustuotos: Lehtiartikkeli › Katsaus › Tieteellinen › vertaisarvioitu
TY - JOUR
T1 - Type 1 Diabetes in Children With Genetic Risk May Be Predicted Very Early With a Blood miRNA
AU - Suomi, Tomi
AU - Kalim, Ubaid Ullah
AU - Rasool, Omid
AU - Laiho, Asta
AU - Kallionpää, Henna
AU - Vähä-Mäkilä, Mari
AU - Nurmio, Mirja
AU - Mykkänen, Juha
AU - Härkönen, Taina
AU - Hyöty, Heikki
AU - Ilonen, Jorma
AU - Veijola, Riitta
AU - Toppari, Jorma
AU - Knip, Mikael
AU - Elo, Laura L.
AU - Lahesmaa, Riitta
N1 - Funding Information: This research was supported by the Academy of Finland, including InFLAMES, SYMMyS, and personalized medicine programs (grant numbers 337530, 292482, 250114, 292482, 294337, 292335, 319280, 314444, 329277, 331790, 296801, 304995, 310561, 314443, and 329278), JDRF, including grants 1-SRA-2016-342-M-R and 1-SRA-2019-732-M-B, the Diabetes Research Foundation (Diabetestutkimussäätiö), the Novo Nordisk Foundation, the Finnish Cancer Foundation, the Sigrid Jusélius Foundation, the Pediatric Research Foundation, Turku University Hospital Special Governmental Grants, and the Special Research Funds for University Hospitals in Finland. This research was also supported by grants from the European Research Council (677943), European Union's Horizon 2020 Research and Innovation Programme (955321), and the European Foundation for the Study of Diabetes. Biocenter Finland and ELIXIR Finland also support our research. Funding Information: Acknowledgments. The authors are grateful to the families of the DIPP study participants and the study group. The authors also thank the personnel of the HLA laboratory at the University of Turku and the islet autoantibody laboratory at the University of Oulu. Marjo Hakkarainen and Sarita Heinonen from Turku Bioscience Centre are acknowledged for their skillful assistance in the laboratory. Next-generation sequencing was performed at the Finnish Functional Genomics Centre, Turku, part of the Biocenter Finland network. The authors acknowledge the Finnish Centre for Scientific Computing for data analysis servers. Funding. This research was supported by the Academy of Finland, including InFLAMES, SYMMyS, and personalized medicine programs (grant numbers 337530, 292482, 250114, 292482, 294337, 292335, 319280, 314444, 329277, 331790, 296801, 304995, 310561, 314443, and 329278), JDRF, including grants 1-SRA-2016-342-M-R and 1-SRA-2019-732-M-B, the Diabetes Research Foundation (Diabetestutkimuss€a€atio€), the Novo Nordisk Foundation, the Finnish Cancer Foundation, the Sigrid Jusélius Foundation, the Pediatric Research Foundation, Turku University Hospital Special Governmental Grants, and the Special Research Funds for University Hospitals in Finland. This research was also supported by grants from the European Research Council (677943), European Union's Horizon 2020 Research and Innovation Programme (955321), and the European Foundation for the Study of Diabetes. Biocenter Finland and ELIXIR Finland also support our research. Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. T.S. and U.U.K. designed experiments, analyzed the data, prepared the figures, and wrote the manuscript. O.R. designed experiments, analyzed data, and wrote the manuscript. A.L., H.K., M.V.-M., M.N., J.M., and T.H. contributed to the design of the study and analysis. H.H., J.I., R.V., J.T., and M.K. were responsible for the DIPP cohort. R.V. and M.K. were responsible for the islet autoantibody analyses. All authors contributed to the final version of the manuscript. R.L. initiated, designed, and supervised the study. L.L.E. participated in the design of the study and analysis and supervised the study. R.L. and L.L.E. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Data and Resource Availability. Analyzed count data from miRNA-seq of the discovery cohort (87 samples from four case-control pairs) and the validation cohort (56 samples from 14 pairs) can be accessed from the ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/) using the accession codes E-MTAB-10959 and E-MTAB-10968, respectively. Other data generated during the current study are available from the corresponding author on reasonable request.
PY - 2022/4
Y1 - 2022/4
UR - http://www.scopus.com/inward/record.url?scp=85128160256&partnerID=8YFLogxK
U2 - 10.2337/dc21-2120
DO - 10.2337/dc21-2120
M3 - Letter
C2 - 35134118
AN - SCOPUS:85128160256
SN - 0149-5992
VL - 45
SP - e77-e79
JO - Diabetes Care
JF - Diabetes Care
IS - 4
ER -